{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:42Z","timestamp":1786986882071,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Medical Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]},{"name":"British Heart Foundation and Cancer Research UK"},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["FS\/14\/55\/30806"],"award-info":[{"award-number":["FS\/14\/55\/30806"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.clinthera.2019.06.012","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T08:09:09Z","timestamp":1566461349000},"page":"1767-1777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Serious Adverse Effects of Extended-release Niacin\/Laropiprant: Results From the Heart Protection Study 2\u2013Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial"],"prefix":"10.1016","volume":"41","author":[{"given":"Richard","family":"Haynes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Valdes-Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemma C.","family":"Hopewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Parish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Landray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Valdes-Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemma C.","family":"Hopewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Parish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Landray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Baigent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Landray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Landray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sleight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Parish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Wincott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"van Leijenhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Mitchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Kuznetsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.06.012_bib1","first-page":"25709","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","author":"Grundy","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2019.06.012_bib2","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2019.06.012_bib3","first-page":"S1","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the european society of cardiology (ESC) and the european atherosclerosis society (EAS)","volume":"217","author":"Catapano","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2019.06.012_bib4","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"The AIM-HIGH Investigators","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.06.012_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","year":"2014","journal-title":"N\u00a0Engl J Medi"},{"key":"10.1016\/j.clinthera.2019.06.012_bib6","unstructured":"Food & Drug Administration. 2016, http:\/\/federalregister.gov\/a\/2016-08887."},{"key":"10.1016\/j.clinthera.2019.06.012_bib7","doi-asserted-by":"crossref","first-page":"40859","DOI":"10.1074\/jbc.M306580200","article-title":"Lipid transfer inhibitor protein defines the participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP)","volume":"278","author":"Paromov","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clinthera.2019.06.012_bib8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2019.06.012_bib9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2019.06.012_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/heartjnl-2015-308055","article-title":"Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomized controlled trials","volume":"102","author":"Goldie","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2019.06.012_bib11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/edrv.21.6.0415","article-title":"Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome","volume":"21","author":"Wajchenberg","year":"2000","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clinthera.2019.06.012_bib12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0026-0495(03)00030-1","article-title":"Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content","volume":"52","author":"Poynten","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2019.06.012_bib13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.metabol.2010.02.013","article-title":"Widespread effects of nicotinic acid on gene expression in insulin-sensitive tissues: implications for unwanted effects of nicotinic acid treatment","volume":"60","author":"Choi","year":"2010","journal-title":"Metabolism"},{"key":"10.1016\/j.clinthera.2019.06.012_bib14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamacardio.2016.1884","article-title":"Association of lipid fractions with risks for coronary artery disease and diabetes","volume":"1","author":"White","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.clinthera.2019.06.012_bib15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2019.06.012_bib16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1161\/CIRCULATIONAHA.111.018259","article-title":"Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the investigation of lipid level management to understand its Impact in atherosclerotic events (ILLUMINATE) trial","volume":"124","author":"Barter","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2019.06.012_bib17","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1742-1241.2008.01938.x","article-title":"Lipid-modifying efficacy and tolerability of extended-release niacin\/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia","volume":"62","author":"Maccubbin","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2019.06.012_bib18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1067\/mhj.2000.109648","article-title":"Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT)","volume":"140","author":"Chesney","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2019.06.012_bib19","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1176\/ajp.126.9.1290","article-title":"Nicotinic acid side effects and toxicity: a review","volume":"126","author":"Mosher","year":"1970","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2019.06.012_bib20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/ATVBAHA.111.241836","article-title":"Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms","volume":"32","author":"Digby","year":"2012","journal-title":"Arterioscler Thromb Vasc Bio"},{"key":"10.1016\/j.clinthera.2019.06.012_bib21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.immuni.2013.12.007","article-title":"Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis","volume":"40","author":"Singh","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.clinthera.2019.06.012_bib22","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jamainternmed.2013.6489","article-title":"Use of niacin in the United States and Canada","volume":"173","author":"Jackevicius","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clinthera.2019.06.012_bib23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJMsb1300760","article-title":"Randomized clinical trials: removing unnecessary obstacles","volume":"369","author":"Reith","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.06.012_bib24","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM196903272801301","article-title":"Platelet function in renal failure","volume":"280","author":"Eknoyan","year":"1969","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.06.012_bib25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.amjcard.2006.08.044","article-title":"Safety of lovastatin\/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system)","volume":"99","author":"Alsheikh-Ali","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2019.06.012_bib26","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181930339X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181930339X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:50:44Z","timestamp":1758963044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181930339X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S014929181930339X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.06.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serious Adverse Effects of Extended-release Niacin\/Laropiprant: Results From the Heart Protection Study 2\u2013Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}